Can Evaxion A/S’s AI-designed polio vaccine concepts reshape the final mile of eradication?
Evaxion A/S unveils AI-designed polio vaccine concepts with eradication potential. Read what this means for vaccine innovation and platform risk.
Pharma & Biotech
Pharma & Biotech
How Chiesi Global Rare Diseases is positioning lomitapide for earlier lifecycle management in HoFH
CHMP backs paediatric lomitapide for HoFH. Read what this means for clinicians, regulators, and rare disease access across Europe.
Pharma & Biotech
Can Merck expand WINREVAIR beyond pulmonary arterial hypertension after CADENCE data?
Can Merck turn WINREVAIR’s CADENCE data into a new treatment path in CpcPH-HFpEF? Read the full analysis of what changes next.
Pharma & Biotech
Why Incyte’s povorcitinib 54-week results matter for hidradenitis suppurativa treatment
Incyte's povorcitinib reaches 71.4% HiSCR50 at 54 weeks in HS. Analysis of what the STOP-HS data mean for the JAK1 class and the treatment landscape.
Pharma & Biotech
Can Takeda’s zasocitinib change the plaque psoriasis treatment ladder after Phase 3 wins?
Takeda’s zasocitinib posted strong Phase 3 psoriasis data. Read what it changes for TYK2 competition, regulation, and oral treatment strategy.
Pharma & Biotech
Why WINREVAIR’s Phase 2 data matters beyond pulmonary arterial hypertension
CADENCE trial data shows sotatercept’s promise in HFpEF-linked pulmonary hypertension. Find out what this means for treatment and regulation.
Medical Devices & Diagnostics
Corcept Therapeutics expands hypercortisolism evidence base with largest US resistant hypertension screening trial
Corcept's MOMENTUM trial finds hypercortisolism in 27.3% of resistant hypertension patients. Explore what this means for screening and treatment. Read more.
Pharma & Biotech
Arrowhead Pharmaceuticals strengthens plozasiran’s severe hypertriglyceridemia case with durable ACC.26 data
Arrowhead Pharmaceuticals’ plozasiran posted durable triglyceride reductions at ACC.26. Read what the long-term data could change next.
Pharma & Biotech
What Galderma’s nemolizumab phase II data mean for the competitive biologic landscape in pediatric eczema
Galderma's nemolizumab phase II data in children aged 2-11 show 52-week itch and lesion relief. Read the analysis.
Pharma & Biotech
Why Kardigan’s Phase 2 tonlamarsen results matter more for acute severe hypertension than chronic blood pressure care
Kardigan’s tonlamarsen showed Phase 2 promise in hypertension, but can it win in acute severe hypertension next? Read the deeper analysis.